

# Tuberculosis profile: Afghanistan

Population 2021: 40 million

## Estimates of TB burden\*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	76 000 (48 000-109 000)	189 (120-272)
HIV-positive TB incidence	5 (1-13)	0.01 (0-0.03)
MDR/RR-TB incidence**	4 800 (0-13 000)	12 (0-31)
HIV-negative TB mortality	12 000 (7 300-19 000)	31 (18-47)
HIV-positive TB mortality	2 (0-4)	0 (0-0.01)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2021

New cases	5.4% (0.6-19)
Previously treated cases	36% (29-44)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2021	66% (46-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	17% (8-28)

## TB case notifications, 2021

Total new and relapse	50 324
- % tested with rapid diagnostics at time of diagnosis	38%
- % with known HIV status	62%
- % pulmonary	75%
- % bacteriologically confirmed ^	67%
- % children aged 0-14 years	22%
- % women (aged ≥15 years)	45%
- % men (aged ≥15 years)	33%
Total cases notified	50 710

## TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	2	0.0064%
- on antiretroviral therapy	2	100%

## Drug-resistant TB care\*\*, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	71%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	56%
Laboratory-confirmed cases - MDR/RR-TB ^^	582
Patients started on treatment - MDR/RR-TB ^^	412
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	123
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	20
MDR/RR-TB cases tested for resistance to any fluoroquinolone	413

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	95%	45 818
Previously treated cases, excluding relapse, registered in 2020		0
HIV-positive TB cases registered in 2020		0
MDR/RR-TB cases started on second-line treatment in 2019	71%	396
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		


## TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	29%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	87% (80-96)


## Funding for TB

Funding for TB, 2021 (US\$ millions)	9
- % domestic funding	8.4%
- % international funding	92%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2021



## Cases attributable to five risk factors, 2021



## Funding for TB (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
\*\* RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
^ Calculated for pulmonary cases only  
^^ Includes cases with unknown previous TB treatment history  
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

---

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)